



Resignation of Director

19th May, 2015, Melbourne: IDT Australia Limited announces that Mr. David Williams has advised his resignation from the IDT Board. His resignation is effective today, and will enable him to devote more time to his other business interests.

IDT wishes to thank Mr. Williams for his 5 years as a Director of the company, and his valuable contributions in the areas of strategy, finance and business development, and also for his work as Chair of the Audit Committee.

“David’s time on the IDT board has spanned a critical and exciting period for IDT as it focused on both restoring the base business, and transitioned into a proprietary specialty generics business. While these processes are not yet complete, David has made a very positive contribution towards establishing the Company on its next phase of growth”, said IDT Chairman, Mr. Graeme Kaufman.

ENDS

For further information please contact:

IDT Australia Limited
Dr Paul MacLeman
Managing Director
(03) 9801 8888

Monsoon Communications
Rudi Michelson
(03) 9620 3333

About IDT

IDT Australia Ltd recently acquired a portfolio of 23 generic drugs to manufacture and sell via US distribution partners. With IDT’s 2013 temozolomide ANDA filing this signifies IDT’s move to rapidly become a specialty generics business with near term revenue build up.

IDT (ASX:IDT) is a public Australian pharmaceutical manufacturing company based in Boronia, Victoria, Australia. It has extensive experience in the development and production of high potency and high containment pharmaceutical products for local and international clients. IDT’s facilities are fully cGMP compliant and are regularly audited by the US FDA and Australian TGA. With an experienced team of specialists within world-class facilities, IDT provides a full-scale service for new drug development and scale-up, commercial active drug manufacture as well as a variety of oral and injectable finished drug dose forms.

Through CMAX, its clinical research services business based at the Royal Adelaide Hospital in South Australia, IDT also provides full Phase I clinical trials management and delivery, recruitment in specific disease states for Phase II and Phase III trials as well as offering trial packaging, distribution and pharmacy services from the cGMP Boronia facilities.